Robert J. Applegate, MD, Mark A. Grabarczyk, MD, David C. Sane, MD, Matthew T. Sacrinty, MPH, Jason E. Goodin, BA, G. Sidney Statonk, MD, Talal T. Baki, MD, Sanjay K. Gandhi, MD, Michael A. Kutcher, MD, William C. Little, MD
The issue that Seems unclear to me is the use of GIIbIIIa drugs upstream in the nonPCI setting. There is abundant evidence to support it's use, FDA approved with or without PCI. And the patients often are delayed by 72 or more hours IF a procedure is anticipated (records indicate that a small % transferred to the PCI center are ultimately treated medically. My sense is that high TIMI risk NSTEMI ACS pts should receive GIIbIIIa therapy unless there is a contraindication . Comment please from those in the mainstream of current therapy. , thank you.
More information about formatting options
Our other resources for healthcare professionals.
HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2014 HMP Communications